Neurological update: MOG antibody disease
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOG-AD) is now recognised as a nosological entity with specific clinical and paraclinical features to aid early diagnosis. Although no age group is exempt, median age of onset is within the fourth decade of life, with optic neuritis being the most frequent presenting phenotype. Disease course can be either monophasic or relapsing, with subsequent relapses most commonly involving the optic nerve. Residual disability develops in 50-80% of patients, with transverse myelitis at onset being the most significant predictor of long-term outcome. Recent advances in MOG antibody testing offer improved sensitivity and specificity. To avoid misdiagnosis, MOG antibody testing should be undertaken in selected cases presenting clinical and paraclinical features that are felt to be in keeping with MOG-AD, using a validated cell-based assay. MRI characteristics can help in differentiating MOG-AD from other neuroinflammatory disorders, including multiple sclerosis and neuromyelitis optica. Cerebrospinal fluid oligoclonal bands are uncommon. Randomised control trials are limited, but observational open-label experience suggests a role for high-dose steroids and plasma exchange in the treatment of acute attacks, and for immunosuppressive therapies, such as steroids, oral immunosuppressants and rituximab as maintenance treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., Correale, J., Fazekas, F., Filippi, M., Freedman, M. S., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30470-2 · Cited by 8,167
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
Wingerchuk, D. M., Banwell, B., Bennett, J. L., Cabre, P., Carroll, W., Chitnis, T., de Seze, J., Fujihara, K., Greenberg, B., Jacob, A., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001729 · Cited by 4,649
Self-citationThe spectrum of neuromyelitis optica
Wingerchuk, D. M., Lennon, V. A., Lucchinetti, C. F., Pittock, S. J., & Weinshenker, B. G. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70216-8 · Cited by 2,179
Ruiter, A. M., Meilof, J. F., Somanje-Bolweg, R. R. J., van Gorsel, E., & Kalkers, N. F. (2017) · Case Reports in Neurology · doi:10.1159/000455942 · Cited by 1,762
in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., Pache, F., Stich, O., Beume, L.-A., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0718-0 · Cited by 899
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
Jarius, S., Paul, F., Aktas, O., Asgari, N., Dale, R. C., de Seze, J., Franciotta, D., Fujihara, K., Jacob, A., Kim, H. J., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1144-2 · Cited by 747
Self-citationClinical presentation and prognosis in MOG-antibody disease: a UK study
Jurynczyk, M., Messina, S., Woodhall, M. R., Raza, N., Everett, R., Roca-Fernandez, A., Tackley, G., Hamid, S., Sheard, A., Reynolds, G., et al. (2017) · Brain · doi:10.1093/brain/awx276 · Cited by 740 · cited 8×
“At presentation, MOG-positive patients are thought to be at lower risk of further relapses than aquaporin 4 (AQP4)positive patients [29] and have better visual and motor outcomes [29, 32].”
BackgroundInfluentialSelf-citationLinington, C., Bradl, M., Lassmann, H., Brunner, C., & Vass, K. (1988) · PubMed · Cited by 708
Berger, T., Rubner, P., Schautzer, F., Egg, R., Ulmer, H., Mayringer, I., Dilitz, E., Deisenhammer, F., & Reindl, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022328 · Cited by 616
Ramanathan, S., Mohammad, S., Tantsis, E., Nguyen, T. K., Merheb, V., Fung, V. S. C., White, O. B., Broadley, S., Lechner-Scott, J., Vucic, S., et al. (2018) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2017-316880 · Cited by 572
Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study
Cobo-Calvo, A., Ruiz, A., Maillart, E., Audoin, B., Zephir, H., Bourre, B., Ciron, J., Collongues, N., Brassat, D., Cotton, F., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005560 · Cited by 538
MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy
Ogawa, R., Nakashima, I., Takahashi, T., Kaneko, K., Akaishi, T., Takai, Y., Sato, D. K., Nishiyama, S., Misu, T., Kuroda, H., et al. (2017) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000322 · Cited by 436
Hacohen, Y., Wong, Y. Y., Lechner, C., Jurynczyk, M., Wright, S., Konuskan, B., Kalser, J., Poulat, A. L., Maurey, H., Ganelin-Cohen, E., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.4601 · Cited by 423
MOG cell-based assay detects non-MS patients with inflammatory neurologic disease
Waters, P., Woodhall, M., O'Connor, K. C., Reindl, M., Lang, B., Sato, D. K., Juryńczyk, M., Tackley, G., Rocha, J., Takahashi, T., et al. (2015) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000089 · Cited by 390
Ramanathan, S., Prelog, K., Barnes, E. H., Tantsis, E. M., Reddel, S. W., Henderson, A. P., Vucic, S., Gorman, M. P., Benson, L. A., Alper, G., et al. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515593406 · Cited by 384
Schluesener, H. J., Sobel, R. A., Linington, C., & Weiner, H. L. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.12.4016 · Cited by 371 · cited 4×
“MOG-AD is an inflammatory demyelinating condition of the CNS characterised by a monophasic or relapsing course of neurological dysfunction, which does not meet the typical criteria for MS or other known neuroinflammatory conditions and occurs in the presence of serum MOG antibodies detected using specific cell-based a…”
BackgroundInfluentialPrognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome
Hennes, E.-M., Baumann, M., Schanda, K., Anlar, B., Bajer-Kornek, B., Blaschek, A., Brantner-Inthaler, S., Diepold, K., Eisenkölbl, A., Gotwald, T., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004312 · Cited by 341
The Structure and Function of Myelin Oligodendrocyte Glycoprotein
Johns, T. G., & Bernard, C. C. A. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0720001.x · Cited by 294
Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis
Bernard, C. C. A., Johns, T. G., Slavin, A., Ichikawa, M., Ewing, C., Liu, J., & Bettadapura, J. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050092 · Cited by 270
Jurynczyk, M., Geraldes, R., Probert, F., Woodhall, M. R., Waters, P., Tackley, G., DeLuca, G., Chandratre, S., Leite, M. I., Vincent, A., et al. (2017) · Brain · doi:10.1093/brain/aww350 · Cited by 265 · cited 1×
“Dawson’s fingers, U- or S-shaped lesions and ovoid lesions adjacent to the body of lateral ventricles are found less commonly [29, 46].”
BackgroundLack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis
Kuhle, J., Pohl, C., Mehling, M., Edan, G., Freedman, M. S., Hartung, H.-P., Polman, C. H., Miller, D. H., Montalban, X., Barkhof, F., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063602 · Cited by 255
in cooperation with the Neuromyelitis Optica Study Group (NEMOS), Pache, F., Zimmermann, H., Mikolajczak, J., Schumacher, S., Lacheta, A., Oertel, F. C., Bellmann-Strobl, J., Jarius, S., Wildemann, B., et al. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0720-6 · Cited by 246
Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution
Matthews, L., Marasco, R., Jenkinson, M., Küker, W., Luppe, S., Leite, M. I., Giorgio, A., De Stefano, N., Robertson, N., Johansen-Berg, H., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e3182887957 · Cited by 225
Linington, C., & Lassmann, H. (1987) · Journal of Neuroimmunology · doi:10.1016/0165-5728(87)90031-2 · Cited by 221
Hamid, S. H. M., Whittam, D., Saviour, M., Alorainy, A., Mutch, K., Linaker, S., Solomon, T., Bhojak, M., Woodhall, M., Waters, P., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3196 · Cited by 214
Self-citationAutoantibodies to MOG in a distinct subgroup of adult multiple sclerosis
Spadaro, M., Gerdes, L. A., Krumbholz, M., Ertl-Wagner, B., Thaler, F. S., Schuh, E., Metz, I., Blaschek, A., Dick, A., Brück, W., et al. (2016) · Neurology Neuroimmunology & Neuroinflammation · doi:10.1212/nxi.0000000000000257 · Cited by 206
Diagnostic algorithm for relapsing acquired demyelinating syndromes in children
Hacohen, Y., Mankad, K., Chong, W. K., Barkhof, F., Vincent, A., Lim, M., Wassmer, E., Ciccarelli, O., & Hemingway, C. (2017) · Neurology · doi:10.1212/wnl.0000000000004117 · Cited by 190
Histopathology and clinical course of MOG-antibody-associated encephalomyelitis
Spadaro, M., Gerdes, L. A., Mayer, M. C., Ertl-Wagner, B., Laurent, S., Krumbholz, M., Breithaupt, C., Högen, T., Straube, A., Giese, A., et al. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.164 · Cited by 176
Mariotto, S., Ferrari, S., Monaco, S., Benedetti, M. D., Schanda, K., Alberti, D., Farinazzo, A., Capra, R., Mancinelli, C., De Rossi, N., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8635-4 · Cited by 165
Peschl, P., Schanda, K., Zeka, B., Given, K., Böhm, D., Ruprecht, K., Saiz, A., Lutterotti, A., Rostásy, K., Höftberger, R., et al. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0984-5 · Cited by 163
MOG antibody-related disorders: common features and uncommon presentations
Cobo‐Calvo, Á., Ruiz, A., d’Indy, H., Poulat, A., Carneiro, M., Nicolas, P., Durand‐Dubief, F., Deiva, K., Vukusic, S., Portes, V. D., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8583-z · Cited by 137
Jarius, S., Metz, I., König, F. B., Ruprecht, K., Reindl, M., Paul, F., Brück, W., & Wildemann, B. (2016) · Multiple Sclerosis Journal · doi:10.1177/1352458515622986 · Cited by 116
Risk of relapse phenotype recurrence in multiple sclerosis
Kalinčík, T., Buzzard, K. A., Jokubaitis, V., Trojano, M., Duquette, P., Izquierdo, G., Girard, M., Lugaresi, A., Grammond, P., Grand’Maison, F., et al. (2014) · Multiple Sclerosis Journal · doi:10.1177/1352458514528762 · Cited by 108
Overlapping CNS inflammatory diseases: differentiating features of NMO and MS
Juryńczyk, M., Craner, M., & Palace, J. (2015) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-308984 · Cited by 101
Karni, A., Bakimer-Kleiner, R., Abramsky, O., & Ben‐Nun, A. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.311 · Cited by 99
Biotti, D., Bonneville, F., Tournaire, E., Ayrignac, X., Dalliere, C. C., Mahieu, L., Vignal‐Clermont, C., Dulau, C., Brochet, B., Ruet, A., et al. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8615-8 · Cited by 80
Nakamura, Y., Nakajima, H., Tani, H., Hosokawa, T., Ishida, S., Kimura, F., Kaneko, K., Takahashi, T., & Nakashima, I. (2017) · BMC Neurology · doi:10.1186/s12883-017-0858-6 · Cited by 75
Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS
Tomassini, V., Giglio, L. D., Reindl, M., Russo, P., Pestalozza, I. F., Pantano, P., Berger, T., & Pozzilli, C. (2007) · Multiple Sclerosis Journal · doi:10.1177/1352458507077622 · Cited by 71
Self-citationWong, Y. Y. M., Hacohen, Y., Armangué, T., Wassmer, E., Verhelst, H., Hemingway, C. A., van Pelt, E. D., Catsman‐Berrevoets, C. E., Hintzen, R. Q., Deiva, K., et al. (2018) · European Journal of Neurology · doi:10.1111/ene.13602 · Cited by 68
Stiebel-Kalish, H., Lotan, I., Brody, J., Chodick, G., Bialer, O., Marignier, R., Bach, M., & Hellmann, M. A. (2017) · PLOS ONE · doi:10.1371/journal.pone.0170847 · Cited by 67
Zhou, L., ZhangBao, J., Li, H., Li, X., Huang, Y., Wang, M., Zhao, C., Lu, J., Lü, C., Li, Y., et al. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.09.023 · Cited by 67
Anti-MOG antibodies in adult patients with demyelinating disorders of the central nervous system
Tanaka, M., & Tanaka, K. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.03.001 · Cited by 62
Antimyelin antibodies and the risk of relapse in patients with a primary demyelinating event
Rauer, S. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.077784 · Cited by 61
Nakamura, M., Iwasaki, Y., Takahashi, T., Kaneko, K., Nakashima, I., Kunieda, T., Kaneko, S., & Kusaka, H. (2017) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2017.07.023 · Cited by 50
Diagnosis and treatment of anti-myelin oligodendrocyte glycoprotein antibody positive optic neuritis
Kezuka, T., & Ishikawa, H. (2018) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-018-0561-1 · Cited by 46
Pittock, S., Reindl, M., Achenbach, S. J., Berger, T., Brück, W., König, F., Morales, Y., Lassmann, H., Bryant, S. C., Moore, S., et al. (2007) · Multiple Sclerosis · doi:10.1177/1352458506072189 · Cited by 45
An unusual case of anti-MOG CNS demyelination with concomitant mild anti-NMDAR encephalitis
Zhou, J., Tan, W., Tan, S. E., Hu, J., Chen, Z., & Wang, K. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.03.019 · Cited by 39
Vieira, J. P., Sequeira, J., & Brito, M. J. (2017) · Journal of Child Neurology · doi:10.1177/0883073817724927 · Cited by 35
Multiple sclerosis lesions: insights from imaging techniques
Tomassini, V., & Palace, J. A. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.83 · Cited by 25
Self-citation
Metadata
- Authors
- Wynford-Thomas, R., Jacob, A., & Tomassini, V.
- Venue
- Journal of Neurology
- Published
- 2018-12-19
- Volume
- 266
- Issue
- 5
- Pages
- 1280-1286
- ISSN
- 0012-1037 (ISSN-L)
- 0340-5354
- 1432-1459
- OpenAlex
- W2905025446
- Cited by
- 235
- References
- 49
- FWCI
- 14.94
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.